Alliance Pharma PLC Update on Diclectin (4885M)
July 28 2017 - 11:21AM
UK Regulatory
TIDMAPH
RNS Number : 4885M
Alliance Pharma PLC
28 July 2017
For immediate release 28 July 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Update on Diclectin
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
company, announces that it has been advised by the UK's regulator,
the Medicines and Healthcare products Regulatory Agency (MHRA),
that the marketing authorisation submission for Diclectin has not
been approved.
Diclectin, a treatment for nausea and vomiting of pregnancy, was
in-licensed from Duchesnay Inc. of Canada ("Duchesnay") for the UK
in 2015 and for a further nine European territories in 2016. The
total amount paid to Duchesnay for all territories was GBP1.5
million.
Whilst this is disappointing news, this will have no material
impact on the Company's expected near-term results.
Certain information contained in this announcement constituted
inside information (as defined by Article 7 of the Market Abuse
Regulation) prior to the dissemination of this announcement.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Officer
Peter Butterfield, Deputy
Chief Executive Officer
Andrew Franklin, Chief Financial
Officer
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUUPMUPMGAR
(END) Dow Jones Newswires
July 28, 2017 11:21 ET (15:21 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024